165 LUDLOW AVENUE, NORTHVALE, NJ
Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information
Amended material disclosure
To Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Announces Commercial Launch of Generic Requip XL®
To Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
Reports Positive Results from a Pivotal Bioequivalence Study
Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Announces Commercial Launch of Methadone Hydrochloride Tablets
Q1
FY 2025
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence